Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2/3 1Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Gastrointestinal 1CNS 1

Conditions

Sarcoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Motor Activity 1Lymphoma 1Leukemia 1Insulin Resistance 1Inflammation 1Endometrial Neoplasms 1Colorectal Neoplasms 1Brain Neoplasms 1

Interventions

pembrolizumab 3Tirzepatide 2Paclitaxel 2Metformin 2Carboplatin 2tislelizumab 1olaparib 1niraparib 1montelukast 1Taxes 1Tablets 1Radiotherapy, Intensity-Modulated 1Progesterone 1Pafolacianine 1Morphine 1Laparotomy 1Hysterectomy 1Fluorescein 1Ezetimibe 1Dasatinib 1Biopsy 1Atorvastatin 1Anti-Inflammatory Agents, Non-Steroidal 1Anesthesia, Local 1Anesthesia, General 1Anesthesia, Conduction 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Endometrial Neoplasms × Tablets × Clear all
NCT06887673 2025-03-20

Lipid Mediators & Cancer: Montelukast, SPM, and Almonds

University of South Florida

Phase EARLY_PHASE1 Not yet recruiting
56 enrolled
CNSGastrointestinalGynecologicSarcoma

Brain Neoplasms, Inflammation, Ovarian Neoplasms, Sarcoma, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡